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The aim of this case report was to present our patient 
suffering from vitiligo vulgaris, and to evaluate clinical 
presentation, diagnostic and therapeutic diffi culties for 
this condition.
Case Report
A 23-year-old Caucasian female patient was admitted 
to the University Hospital Center »Sestre milosrdnice«, in 
September 2010, due to prominent, generalized depig-
mented patches.
The disease began acutely, »over night« (in patients̀  
own words), and progressed in the following order: dorsal 
aspects of hands, upper extremities, trunk, face and lower 
extremities. Within a few weeks 60% of her body was af-
fected.
On admission to the hospital her height was 175 centi-
meters and weight was 60 kilograms, and the body mass 
index was normal (19.6). She was Fitzpatrick’s phototype 
II.
Vitiligo is an acquired chronic disease characterized 
by depigmented macular patches due to loss of epidermal 
melanocytes1,2. According to our statistical data, it affects 
1.6% of the general population in Croatia. Female patients 
are more affected (53.95%) than male patients, with no 
difference in severity of vitiligo. Although most of our ad-
mitted patients have been in generally good health, viti-
ligo vulgaris is associated with a number of other autoim-
mune diseases, such as autoimmune thyroid disease, 
diabetes mellitus, pernicious anemia, rheumatoid arthri-
tis, and lupus erythematosus. The localized form of viti-
ligo most frequently affects 21 to 28-year-old patients, 
while generalized form prevails in the age group from 29 
to 36 years. Patients older than 77 years of age are very 
rarely affected. The most common localized type was focal 
(93.28%), and the most common generalized type was 
vitiligo vulgaris (53.7%). Most of our patients were admit-
ted in September, probably due to increased contrast be-
tween involved and uninvolved skin during prolonged sun 
exposure. Most patients attribute the onset of their dis-
ease to specifi c life events (physical injury, emotional dis-
tress, illness or pregnancy).
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A B S T R A C T
Vitiligo is an acquired, chronic, multifactorial disorder which involves complex interactions between genetic risk fac-
tors and environmental triggers. It is characterized by scattered circumscribed depigmented macules and patches any-
where on the skin that result from loss of functional melanocytes. According to our statistical data, 1.6% of the general 
population in Croatia suffers from vitiligo, but varies based on region. It affects all age groups equally, with female patients 
being more affected (53.95%) than male patients, and no difference in severity of vitiligo. We present a case of a sudden 
onset of vitiligo vulgaris from a female patient in her twenties, treated at the Department of Dermatology and Venereol-
ogy. Her 12-year-old brother simultaneously developed acrofacial vitiligo, six months after their mother died in a car 
accident. She has been previously diagnosed with type I diabetes and autoimmune endocrinopathies. The depigmented 
patches covered approximately 60% of her body, with Koebner response on trauma. Although no characteristic UV fl uo-
rescence was detected on the affected area, histopathological and immunohistochemical analyses revealed a complete loss 
of melanocytes, while Langerhans̀  and dermal dendritic cells replaced the DOPA-positive melanocytes. TSH levels were 
elevated, and the ultrasound showed thyroid enlargement, which substantiated for a hypothyroidism therapy. Treatment 
by systemic corticosteroids for a 6 month period was successful in stabilizing the disease.
Key words: pigmentation disorders, melanocytes, vitiligo, case
Introduction
Received for publication June 5, 2014
1192
V. Bulat et al.: Vitiligo in Croatia, Coll. Antropol. 38 (2014) 4: 1191–1194
The affected area had no associated scaling. There was 
a lack of cutaneous induration or sclerosis. Skin lesions 
were asymptomatic and lacked clinical sings of infl amma-
tion. During dermatological examination leukotrichia of 
the occipital area was found. There was no mucosal in-
volvement. She was without any subjective diffi culties (e.g. 
pain, fever, weight loss).
There was a family history for this disorder; patient’s 
12-year-old brother has acrofacial vitiligo. The disease ap-
peared almost simultaneously in both siblings. The onset 
of disease was attributed to emotional stress; after their 
mother had died in a car accident 6 months earlier, patient 
noticed the fi rst lesions of vitiligo. She also noticed new 
depigmented lesions in sites of physical injury (Koebner 
phenomena).
The history of chronic sun exposure was negative. She 
was a non-smoker.
Illumination with Wood`s lamp showed no fl uorescence 
of affected depigmented skin.
Vitiligo vulgaris has been diagnosed based on the 
clinical picture and pathohistological appearance. On ad-
mission, excisional biopsy of depigmented and non-lesion-
al skin was performed.
Histopathological analysis of lesional skin has shown 
characteristic histologic features of vitiligo, such as total 
loss of melanocytes of the basal layer of the epidermis. 
Collagen fi bers were not affected. There was no epidermal 
alteration or cellular infi ltrate. Immunohistochemical ana-
lysis revealed the absence of melanocytes, without DOPA-
positive melanocytes, which appear to be replaced by 
Langerhans̀  and dermal dendritic cells.
The diagnostic and laboratory tests have been per-
formed during hospitalization. Obtained fi ndings were 
within normal limits. Obtained echocardiogram and ab-
dominal ultrasound were without signifi cant changes. Ocu-
lar fundus on ophthalmological examination showed ab-
sence of depigmented lesions. She had no hearing problems.
Serology for Borrelia burgdorferi in our patient was 
negative.
Cytomegalovirus serology and Epstein-Barr virus spe-
cifi c serologies were negative. Serum level of tumor markers 
(CA 19-9, CEA, CA 125, CA 15-3, and CYFRA 21-1) was 
normal as well. HLA typing was positive for HLA A2, B51, 
B62, DR11, DR13, DR52, DQ1 and 3. In addition, our patient 
had autoimmune endocrinopathies; type I, insulin-depen-
dent diabetes was diagnosed when she was 10 years old.
A serum thyroid-stimulating hormone (TSH) level and 
antithyroperoxidase antibodies were elevated, while T4 
level was low. Additional laboratory fi ndings include anti-
thyroglobulin antibodies were within normal range. Ul-
trasound imaging of the thyroid gland revealed diffuse 
enlargement of the thyroid gland, so she was started on 
levothyroxine for hypothyroidism.
Results
Oral mini-pulse corticosteroid therapy (prednisolone) 
for 6 months has shown the ability to stabilize the disease 
with no exacerbations.
Topical class III corticosteroids were used for depig-
mented patches on her arms twice daily for two months, 
resulting in several perifollicular repigmentations. She 
had developed several side-effects such as atrophy and 
telangiectasiae. Topical 0,1% tacrolimus ointment was 
used for face and intertriginous areas twice daily for two 
months, but with no apparent success.
Narrow-band UVB was applied for six months with the 
total of 48 exposures. The starting dose was 250 mJ/cm2, 
with 10% increments at each subsequent exposure. Treat-
ment was administered two times per week but never on 
two consecutive days. Following the aforementioned ther-
apeutic scheme, neither perifollicular repigmentation nor 
repigmentation from the periphery was detected.
Discussion and Conclusion
Vitiligo is an acquired, common, chronic disorder char-
acterized by scattered circumscribed depigmented mac-
ules and pathes which vary in number and size3.
Based on distribution, vitiligo is classifi ed as: localized 
comprising unilateral depigmented macules following seg-
mental (dermatomal) or focal pattern; generalized com-
prising acrofacial pattern involving face and distal ex-
tremities; and vitiligo vulgaris with widespread, usually 
symmetrically distributed lesions; universal vitiligo with 
complete or nearly complete depigmentation, and mucosal 
vitiligo presenting with typical depigmented macules ex-
clusively on mucosal surfaces4,5.
Our 23-year old female patient was diagnosed with 
generalized vitiligo, the most frequent type, based on the 
clinical presentation, history and histopathological fi nd-
ings. Occurrence of vitiliginous lesions within the areas 
of physical trauma or friction, known as Koebner phenom-
enon in vitiligo patients has been well described in litera-
ture and was also documented in our patient6. Occasion-
ally there are circumscribed areas of white hair known as 
leukotrichia such as found in occipital region in our case1,7. 
Other potential associated fi ndings include prematurely 
gray hair and audiovisual disturbances, which we did not 
fi nd1,5. Skin and/or mucosal lesions are usually asymptom-
atic and gradually progress to involve larger areas, with 
unpredictable course and extent of skin/mucosal involve-
ment4. Halo nevi may precede vitiliginous skin lesions, or 
may be found concomitantly1,5. At admission to our De-
partment the patient had one halo nevus in her right 
scapular region.
Consistent with our histopathological fi ndings, there 
is absence of melanocytes and infl ammatory infi ltrate in 
fully developed vitiligo lesions, although superfi cial der-
mal perivascular and perifollicular lymphocytic infi ltrate 
may be detected at the margin of lesions in early lesions8. 
On electron microscopy, which was not performed in our 
case, absence of melanocytes and melanosomes in kerati-
nocytes is documented1. Despite straightforward clinical 
appearance of vitiligo in majority of cases, several addi-
tional diagnostic procedures may be needed for confi rma-
tion of diagnosis in some less clear cases. Patients with 
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vitiligo should be examined under both visible and ultra-
violet light of about 365 nm wavelengths (i.e. Wood`s lamp) 
in order to exclude tinea versicolor (varietas alba)1.
Vitiligo can also resemble macules in idiopathic guttate 
hypomelanosis (IGH), pityriasis alba, postinfl ammatory 
hypopigmentation, chemical leukoderma, leukoderma as-
sociated with melanoma, sarcoidosis, hypomelanosis of 
Ito, nevus anemicus, piebaldism, leprosy, Vogt-Koyanagi-
Harada syndrome and Waardenburg syndrome1,5.
The important entities in differential diagnosis for vi-
tiligo are also lichen sclerosus et atrophicus, congenital 
hypomelanotic macules of tuberous sclerosis, and hypop-
igmented mycosis fungoides. Excisional biopsy of perile-
sional skin should be performed1,5.
According to the epidemiological data, vitiligo has a 
worldwide prevalence of 0.1–2%, equally affecting both 
sexes5,8. Croatian statistical data is within this range with 
female patients being overpresented. An apparent female 
predominance is probably the result of heightened percep-
tion of a cosmetic problem. Although vitiligo may appear 
at any age, from shortly after birth to late adulthood, most 
studies report that the average age of disease onset is 
18–30 years of age, consistent with our patient’s age9–11.
Vitiligo is a multifactorial disorder, therefore, several 
hypotheses regarding the etiopathogenesis of vitiligo ex-
ist. The importance of genetic background is supported by 
studies demonstrating signifi cantly higher (7–10 times) 
incidence of vitiligo among fi rst degree relatives. Familial 
occurrence of vitiligo is present in approximately 20% of 
cases and is characterized by polygenic, non-Mendelian 
inheritance with incomplete penetrance and multiple sus-
ceptibility loci. Notably, studies suggest earlier onset of 
disease in familial vitiligo as opposed to non-familial, so 
our case report refl ects those from the literature12. Certain 
HLA types have been frequently associated with vitiligo 
worldwide, primarily HLA A2 also found in our case, DR4, 
DR7 and Cw61,14.
Emotional stress, such as death of a close relative or 
other psychological trauma of similar intensity is a well-
documented trigger of vitiligo in susceptible patients, just 
as described in our patient whose parent’s death had been 
followed by appearance of vitiligo in her and her brother15. 
Numerous studies demonstrate that mental stress can 
directly and/or indirectly infl uence the survival and struc-
tural integrity of melanocytes15,16. Neurogenic factors in-
fl uenced by mental stress, such as neuropeptide Y (NPY), 
calcitonin gene-related peptide (CGRP), catecholamines, 
and nerve growth factor (NGF), lead to melanocyte de-
struction15.
Several comorbidities have been associated with viti-
ligo; among them the most frequent are autoimmune dis-
eases such as thyroid-related disorders (Hashimoto’s or 
Graves’s disease), followed by psoriasis, diabetes mellitus 
type I, rheumatoid arthritis, alopecia areata, infl amma-
tory bowel disease and systemic lupus erythematosus17. 
Our patient had been previously diagnosed with diabetes 
mellitus type I. Following laboratory workup, elevated 
thyroid-stimulating hormone (TSH) level was detected 
and thyroid gland enlargement was revealed on ultra-
sound imaging. These fi ndings were consistent with 
Hashimoto’s thyroiditis, as confi rmed by endocrinologist’s 
examination. Positive family history for Hashimoto’s thy-
roiditis was obtained, involving the patient’s deceased 
mother who had been diagnosed with this autoimmune 
disease. Of note, some suggestions have been made in the 
literature that individuals from families with an increased 
prevalence of thyroid disease, vitiligo and diabetes mel-
litus have increased risk for development of vitiligo17. Re-
cently published study displayed evidence that non-seg-
mental vitiligo associated with autoimmune thyroid 
disease in comparison with vitiligo without autoimmune 
thyroid disease has distinct clinical features consistent 
with our fi ndings; female sex, greater body surface in-
volvement, longer duration of disease and family history 
of autoimmune thyroid disease. It is therefore suggested 
that these patients should be monitored for thyroid dis-
ease18. Antinuclear antibodies, frequently found in vitiligo 
patients, were not detected in our patient’s serum9. Among 
other conditions associated with vitiligo, low serum levels 
of 25-hydroxy vitamin D or frank vitamin D defi ciency is 
also observed19. Interestingly, higher Fitzpatrick skin pho-
totypes seem to correlate with lower serum 25-hydroxy 
vitamin D levels and a greater risk for vitamin D defi -
ciency19. Although there has been no correlation concern-
ing serum vitamin D levels and severity of vitiligo, it has 
been observed that patients with very low levels of serum 
vitamin D (<15 ng/mg) have substantially increased risk 
for another autoimmune disease, predominantly systemic 
lupus erythematosus, Sjögren’s syndrome, Hashimoto’s 
thyroiditis, Graves’ disease, alopecia areata and infl am-
matory bowel disease19. In our case serum vitamin D 
level was within normal range.
Inspite of many different theories about the etiopatho-
genesis of vitiligo, its cause remains unknown, although 
evidence confirming autoimmune mechanisms have 
gained the most attention so far. Therefore, treatment mo-
dalities remain limited, whereas treatment approach is 
preferentially individualized and polyvalent. In our case, 
success of treatment including systemic and topical corti-
costeroids, topical calcineurin inhibitor and narrow-band 
phototherapy was modest, accompanied by diminished 
patient compliance and satisfaction20. Another possible 
approach for patients with >50% of skin involvement is to 
consider depigmentation techniques using hydroquinone 
monobenzyl ether or 4-methoxyphenol alone or in combi-
nation with Q-switched ruby laser4. This approach has not 
been tried on our patient yet.
A universal treatment for vitiligo remains to be discov-
ered. Taking our results into account and after reviewing 
recently published literature on this topic, we would like 
to accentuate the need for more comprehensive approach 
to vitiligo in the future. More precise defi nitions of various 
vitiligo subtypes should be obtained. Disease severity, 
progression and duration should also be implemented into 
these variables. Each treatment should be individualized 
and several treatment modalities should be applied simul-
taneously. Treatment outcome should be evaluated by re-
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pigmentation and its maintenance, cosmetic acceptability, 
quality of life, stabilization of vitiligo and adverse effects 
of therapy. With these requests fulfi lled, perhaps some 
future studies of vitiligo and its treatment modalities 
could be more unifying, clear, easily interpreted and ap-
plicable to our everyday practice.
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VITILIGO U HRVATSKOJ: PRIKAZ SLUČAJA
S A Ž E T A K
Vitiligo je stečena, kronična, multifaktorijalna bolest koja predstavlja složeno međudjelovanje genetičkih i okolišnih 
rizičnih čimbenika. Klinički se bolest očituje pojavom diseminiranih, depigmentiranih makula i areala na koži bilo 
kojeg dijela tijela kao posljedica gubitka funcionalnih melanocita. Prema statističkim podacima, 1,6% opće populacije 
Republike Hrvatske boluje od vitiliga, incidencija varira ovisno o geografskom području. Podjednako zahvaća sve dobne 
skupine, češće žene (53,95%), bez razlike u težini kliničke slike. Predstavljamo slučaj bolesnice kod koje se akutno raz-
vio vulgarni vitiligo, te je primljena i liječena u našoj Klinici za kožne i spolne bolesti. Gotovo istovremeno, njezin 12-o 
godišnji brat je razvio akrofacijalni oblik vitiliga, šest mjeseci nakon što je njihova majka nastradala u prometnoj nesreći. 
Prethodno joj je dijagnosticiran dijabetes tip I uz ostale autoimune endokrinopatije. Depigmentirani areali su zahvatili 
približno 60% površine tijela, uz pozitivan Koebnerov fenomen. Iako nije uočena karakteristična UV fl uorescencija na 
obuhvaćenom području, patohistološke te imunohistokemijske analize su otkrile potpun gubitak melanocita, dok su 
DOPA-pozitivni melanociti zamijenjeni Langerhansovim stanicama i dermalnim dendritičkim stanicama. Razina TSH 
je bila povišena, a ultrazvučnim pregledom je uočena uvećana štitnjača, što je rezultiralo uvođenjem nadomjesne tera-
pije za hipotireozu. Liječenje sistemnim kortikosteroidima u periodu od 6 mjeseci uspješno je stabiliziralo bolest.
